Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Dicerna Pharmaceuticals' (DRNA) CEO Doug Fambrough on Q2 2019 Results - Earnings Call Transcript

BioMarin Pharmaceutical

Global Blood Therapeutics

Iovance Biotherapeutics

Krystal Biotech

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing.

5 Strong Buy Biotech Stocks for the Second Half

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q1 2019 Results - Earnings Call Transcript

RNA interference therapies have seen rough waters during the former half of this decade with little positive news.

Dicerna Pharmaceuticals Continues To Successfully Hit The Target

DRNA earnings call for the period ending December 31, 2018.

News for Dicerna Pharmaceuticals Stock (DRNA)